PTPRC and neoplasm: tumor and/or ascitic fluid of 16 patients were characterized for MSCs phenotype (CD73, CD90, CD105), CSCs markers (CD24, CD44, CD133), and hematopoietic stem and progenitor marker (CD34) and leukocyte common antigen (CD45).